Why do biomarker testing for early-stage non-small cell lung cancer?

- Panels that detect biomarkers can help identify potential treatment options. They may also lead to better outcomes. In fact, biomarker-informed adjuvant therapies significantly reduced mortality in patients with stage IB, II, or IIIA EGFR-mutated NSCLC disease.¹
- Immuno-oncology-based therapies may be beneficial for patients when cancer mutation and PD-L1 status is known.²
- Current guidelines recommend targeted chemotherapy and/or immunotherapy for early-stage NSCLC.

Why should I have the Early-stage NSCLC Panel done?

- In the US, lung cancer is the second most common cancer. It is the leading cause of cancer-related deaths.
- If lung cancer is found in an early stage, there is a higher likelihood of treatment with a positive outcome.
- Biomarker-assisted therapy selection can lead to longer disease-free survival.

Recent phase 3 clinical trial publications support the use of biomarker testing at Stage I-IIIA NSCLC

Recent phase 3 clinical trial publications support the use of biomarker testing at Stage I-IIIA NSCLC

Talk to your doctor about NeoGenomics’ Early-stage NSCLC Panel today!

How can the Early-stage NSCLC Panel help in my cancer journey?

Early-stage Non-Small Cell Lung Cancer Panel can help you and your care team by analyzing genes that are most relevant to therapy selection and prognosis for early-stage lung cancer using a panel of recognized biomarkers such as:

- **EGFR** – Is a protein on cells that helps them grow
- **ALK** – Helps the development of the nervous and gut systems
- **ROS1** – Gene receptor that is a regulator of normal cell possesses
- **PD-L1** – Protein that is thought to be a co-inhibitory factor of the immune response

Talk to your care team about the Early-stage NSCLC Panel

Consider asking the following questions:

- How can the Early-stage NSCLC Panel be used in my treatment plan?
- When should I get tested?
- How often will I need to get tested?
- Will I need another tissue biopsy later in my treatment?
- What can the Early-stage NSCLC Panel results tell me about my cancer?
- What resources are available to me?

**Still have questions? Write them here so you remember what to ask:**

Contact a patient advocate today to learn more.

Email: patients@neogenomics.com
Phone: 866.776.5907, option 9

When will I get my results?

Once our lab receives your sample, testing takes 7 days. Your results will be provided to your care team as soon as they are available.

Have more questions about the Early-stage NSCLC Panel? Our Patient Advocate team is here to help.

![Patient Portal](qr_code.png)

![Patient Website](qr_code.png)